3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Mesothelioma
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Cyclophosphamide
77
Docetaxel
69
Capecitabine
64
Trastuzumab
61
Paclitaxel
50
Tamoxifen
47
Epirubicin
47
Letrozole
44
pyrotinib
40
Fulvestrant
37
Doxorubicin
35
Vinorelbine
33
Radiotherapy
32
Carboplatin
32
Anastrozole
28
exemestane
27
Neoadjuvant Therapy
24
Drug Therapy
22
Fluorouracil
21
palbociclib
20
Exercise
20
Chemotherapy, Adjuvant
19
Bevacizumab
18
pertuzumab
16
Goserelin
16
Cisplatin
16
liposomal doxorubicin
15
Mammography
14
Gemcitabine
14
Blood Specimen Collection
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Breast Neoplasms
×
IPI-549
×
Clear all
NCT03961698
2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2
Unknown
91 enrolled